PBR-06

Synucleinopathies

Brigham and Women's HospitalSmall moleculeActive

D

30/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 15/ 100
Competitive Position: 95/ 100

Competitive context

3 Active assets in the Synucleinopathies cohort.

Asset / Sponsor	Phase	Rating
Tvp-1012 Second Affiliated Hospital, School of Medicine, Zhejiang University	Phase 2/3	B
Donanemab Eli Lilly and Company	Phase 2	CCC
RDX-013 COMPONENT TENAPANOR Cedar Valley Digestive Health Center	Phase 2	CCC
[18F]MNI-1216 Invicro	Early Phase 1	NR

Same molecule, other indications

PBR-06 is also rated in:

relapsing-remitting multiple sclerosisDormant

CCC

Indicative ·

55 / 100

stroke disorderDormant

CC

Indicative ·

47 / 100

multiple sclerosisDormant

CC

Indicative ·

45 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.